Akari Secures $8.3M in Q2 Capital, Completing PIPE and Extending Runway
AKTX has more than doubled off its 52-week low of $3.015 on light trading volume (0.1× avg).
Summary
Akari Therapeutics has completed its previously announced PIPE and received additional proceeds from warrant exercises, securing approximately $8.3 million in capital during Q2 2026. This critical funding directly addresses the company's going concern warning and extends its cash runway, which was previously projected to end in June 2026, as reported in the Q1 2026 filing. The capital is earmarked to advance the lead candidate, AKTX-101, towards a Phase 1 clinical trial. This financing is highly significant given the company's small market cap and immediate liquidity needs. Shareholder approval for the associated Series H, I, and J warrants is pending at the June 30th Annual General Meeting.
At the time of this announcement, AKTX was trading at $9.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.3M. The 52-week trading range was $3.02 to $49.60. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.